These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9514436)

  • 1. Nifedipine and verapamil inhibit the sigmoid colon myoelectric response to eating in healthy volunteers.
    Bassotti G; Calcara C; Annese V; Fiorella S; Roselli P; Morelli A
    Dis Colon Rectum; 1998 Mar; 41(3):377-80. PubMed ID: 9514436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of calcium channel blockers on intestinal motility in the dog.
    De Ponti F; D'Angelo L; Frigo GM; Crema A
    Eur J Pharmacol; 1989 Sep; 168(2):133-44. PubMed ID: 2606145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dihydropyridine calcium channel antagonists disrupt migrating myoelectric complexes and counteract intestinal disorders associated with morphine withdrawal diarrhea.
    Thollander M; Hellström PM; Svensson TH
    Scand J Gastroenterol; 1993 Feb; 28(2):137-44. PubMed ID: 8441907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nifedipine reduces the colonic motor response to eating in patients with the irritable colon syndrome.
    Narducci F; Bassotti G; Gaburri M; Farroni F; Morelli A
    Am J Gastroenterol; 1985 May; 80(5):317-9. PubMed ID: 3993632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal rectosigmoid myoelectric response to eating in patients with severe idiopathic constipation (slow-transit type).
    Bassotti G; Morelli A; Whitehead WE
    Dis Colon Rectum; 1992 Aug; 35(8):753-6. PubMed ID: 1643998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of verapamil on human intestinal transit.
    Krevsky B; Maurer AH; Niewiarowski T; Cohen S
    Dig Dis Sci; 1992 Jun; 37(6):919-24. PubMed ID: 1587197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired colonic motor response to eating in patients with slow-transit constipation.
    Bassotti G; Imbimbo BP; Betti C; Dozzini G; Morelli A
    Am J Gastroenterol; 1992 Apr; 87(4):504-8. PubMed ID: 1553939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age and severe adverse drug reactions caused by nifedipine and verapamil. Gruppo Italiano di Farmacovigilanza nell' Anziano (GIFA).
    Pahor M; Manto A; Pedone C; Carosella L; Guralnik JM; Carbonin P
    J Clin Epidemiol; 1996 Aug; 49(8):921-8. PubMed ID: 8699214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Slow channel inhibitors verapamil and nifedipine in the management of hypertension.
    Gould BA; Hornung RS; Mann S; Balasubramanian V; Raftery EB
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S369-73. PubMed ID: 6184570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in colonic tone and phasic response to a meal in the transverse and sigmoid human colon.
    Ford MJ; Camilleri M; Wiste JA; Hanson RB
    Gut; 1995 Aug; 37(2):264-9. PubMed ID: 7557579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physical Symptoms Distress Index: a sensitive tool to evaluate the impact of pharmacological agents on quality of life.
    Anderson RB; Hollenberg NK; Williams GH
    Arch Intern Med; 1999 Apr; 159(7):693-700. PubMed ID: 10218748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ca2+ channel blockers stimulate ileal and colonic water absorption.
    Donowitz M; Levin S; Powers G; Elta G; Cohen P; Cheng H
    Gastroenterology; 1985 Oct; 89(4):858-66. PubMed ID: 2993090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection by Ca2+ channel blockers (nifedipine, diltiazem and verapamil) against the toxicity of oxidized low density lipoprotein to cultured lymphoid cells.
    Nègre-Salvayre A; Salvayre R
    Br J Pharmacol; 1992 Nov; 107(3):738-44. PubMed ID: 1472971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of lipid intake in meals on the duodenojejunal and sigmoid motor responses in healthy volunteers].
    Zalar A; Riachi G; Heresbach D; Guédon C; Denis P; Ducrotté P
    Gastroenterol Clin Biol; 1996 Feb; 20(1):2-7. PubMed ID: 8734305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium-entry blocking agents in the treatment of systemic hypertension.
    Robinson BF
    Am J Cardiol; 1985 Jan; 55(3):102B-106B. PubMed ID: 2857516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on calcium-channel blocking agents.
    Talbert RL; Bussey HI
    Clin Pharm; 1983; 2(5):403-16. PubMed ID: 6354566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of intraocular pressure by calcium channel blockers.
    Beatty JF; Krupin T; Nichols PF; Becker B
    Arch Ophthalmol; 1984 Jul; 102(7):1072-6. PubMed ID: 6743086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of nifedipine and other calcium antagonists in patients with primary esophageal motor dysfunctions.
    Baunack AR; Weihrauch TR
    Arzneimittelforschung; 1991 Jun; 41(6):595-602. PubMed ID: 1930346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease.
    Packer M; Medina N; Yushak M
    J Am Coll Cardiol; 1984 Nov; 4(5):890-901. PubMed ID: 6491082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcutaneous electrosigmoidography. Study of the myoelectric activity of sigmoid colon by surface electrodes.
    Shafik A
    Front Biosci; 1996 Jul; 1():b1-4. PubMed ID: 9159196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.